Board of DirectorsMeet the Board of Directors in Sanos Group
Chairman of the Board of Directors, InvestCorp
Daniel Lopez-Cruz is the head of Investcorp’s European Private Equity group and a member of Investcorp’s global private equity investment committee. Since joining Investcorp in 2005, Daniel has been responsible for a number of private equity investments across a wide range of industries and European countries. He currently sits in the boards of Agromillora and SPG Prints and has previously served on the boards of Polyconcept, Icopal, Asiakastieto and Esmalglass.
Prior to Investcorp, Daniel was an Executive Director in Morgan Stanley’s investment banking group in New York and London and was previously a Director in UBS’s investment banking group in New York.
Board Member, InvestCorp
Celine Infeld joined Investcorp in 2020. Prior to Investcorp Celine was the Group Managing Director of the Insight Group at Infopro Digital (formerly Incisive Media). During 12 years at Incisive Media, Celine held leadership positions in Sales, Strategy & M&A and Marketing, Product & Digital. Celine started her career at L.E.K. Consulting in both London and San Francesco.
Celine currently sits on the boards of Cambio Healthcare Systems, Georg Jensen and Sanos Group.
Board Member, InvestCorp
Sebastian Inger joined InvestCorp in 2013. Prior to InvestCorp he worked in the industrial team at Credit Suisse in London. Previously he worked at Swedbank in Sweden, in both the equity research team and corporate finance division.
Sebastian has been the Board Director for Sanos Group A/S since December 2020 and is also currently sitting on the boards of Cambio Healthcare Systems, Abax and Georg Jensen.
Jeppe Ragnar Andersen
Group CEO, Sanos Group
Jeppe holds a master’s in Pharmaceutical Science (M.Sc. Pharm) from University of Copenhagen, Denmark, and joined Nordic Bioscience in 2007 as a CRA. In 2010 he became Head of Clinical Development in 2010, and in 2014 he transitioned into his position as the CEO of NBCD.
Jeppe has been involved on an operational and executive level in numerous clinical studies with more than 15,000 patients within various therapeutic fields but primarily within osteoporosis and osteoarthritis leading to market approved drugs in both indications. Jeppe has been leading the company from 3 employees to more than 100.
With his history of success in building and growing organizations, his strong expertise from both CRO and Investigator perspective, and his in-depth project leadership in clinical development, he has an ability to identify market trends and conceptualize strategies with an aim of innovation to improve work and business processes.